HighTower Advisors
ACRS icon

HighTower Advisors’s Aclaris Therapeutics ACRS Stock Holding History

HighTower Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Sell
305,836
-112
-0% -$378 ﹤0.01% 2091
2025
Q4 		$921K Sell
305,948
-3,369
-1% -$8.51K ﹤0.01% 2186
2025
Q3 		$588K Sell
309,317
-12,500
-4% -$21.8K ﹤0.01% 2482
2025
Q2 		$457K Buy
321,817
+5,753
+2% +$7.79K ﹤0.01% 2600
2025
Q1 		$484K Buy
316,064
+53,116
+20% +$113K ﹤0.01% 2483
2024
Q4 		$652K Sell
262,948
-42,866
-14% -$107K ﹤0.01% 2272
2024
Q3 		$352K Sell
305,814
-6,900
-2% -$8.46K ﹤0.01% 2685
2024
Q2 		$344K Buy
312,714
+100
+0% +$118 ﹤0.01% 2605
2024
Q1 		$386K Sell
312,614
-30,410
-9% -$36.3K ﹤0.01% 2476
2023
Q4 		$361K Sell
343,024
-26,778
-7% -$81.7K ﹤0.01% 2573
2023
Q3 		$2.53M Sell
369,802
-10,000
-3% -$85.5K ﹤0.01% 1254
2023
Q2 		$3.94M Buy
379,802
+187,479
+97% +$1.7M 0.01% 1006
2023
Q1 		$1.56M Sell
192,323
-101
-0.1% -$1.28K ﹤0.01% 1434
2022
Q4 		$3.03M Buy
192,424
+134,071
+230% +$2.16M 0.01% 1060
2022
Q3 		$919K Sell
58,353
-1,739
-3% -$27.4K ﹤0.01% 1657
2022
Q2 		$840K Sell
60,092
-3,207
-5% -$44.9K ﹤0.01% 1740
2022
Q1 		$1.09M Sell
63,299
-4,580
-7% -$62.5K ﹤0.01% 1707
2021
Q4 		$987K Sell
67,879
-399
-0.6% -$6.04K ﹤0.01% 1767
2021
Q3 		$1.23M Buy
68,278
+3,800
+6% +$60.9K ﹤0.01% 1539
2021
Q2 		$1.13M Hold
64,478
– – ﹤0.01% 1560
2021
Q1 		$1.62M Buy
64,478
+6,978
+12% +$136K 0.01% 1252
2020
Q4 		$373K Sell
57,500
-2,185
-4% -$9.22K ﹤0.01% 1790
2020
Q3 		$153K Sell
59,685
-9,950
-14% -$22.3K ﹤0.01% 2158
2020
Q2 		$113K Hold
69,635
– – ﹤0.01% 2108
2020
Q1 		$72K Buy
69,635
+10,000
+17% +$13.6K ﹤0.01% 1973
2019
Q4 		$113K Hold
59,635
– – ﹤0.01% 2067
2019
Q3 		$65K Buy
59,635
+562
+1% +$797 ﹤0.01% 2205
2019
Q2 		$130K Sell
59,073
-130
-0.2% -$709 ﹤0.01% 2129
2019
Q1 		$355K Sell
59,203
-10,203
-15% -$67.6K ﹤0.01% 1643
2018
Q4 		$512K Sell
69,406
-5,428
-7% -$55.9K ﹤0.01% 1335
2018
Q3 		$1.09M Buy
74,834
+9,018
+14% +$155K 0.01% 1089
2018
Q2 		$1.31M Sell
65,816
-12,000
-15% -$222K 0.01% 1007
2018
Q1 		$1.36M Sell
77,816
-51,800
-40% -$1.1M 0.01% 951
2017
Q4 		$3.2M Sell
129,616
-14,543
-10% -$354K 0.03% 654
2017
Q3 		$3.72M Buy
144,159
+200
+0.1% +$5.36K 0.03% 588
2017
Q2 		$3.9M Buy
143,959
+68
+0% +$1.85K 0.03% 555
2017
Q1 		$4.29M Buy
143,891
+81,603
+131% +$2.35M 0.04% 488
2016
Q4 		$1.69M Buy
62,288
+10,402
+20% +$265K 0.02% 760
2016
Q3 		$1.33M Hold
51,886
– – 0.02% 812
2016
Q2 		$959K Buy
+51,886
New +$1.03M 0.01% 900

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors's ACRS Position: Q1 2026 in Review

HighTower Advisors reduced its Aclaris Therapeutics (ACRS) stake by 0.04% in Q1 2026, selling an estimated $378 and leaving 305,836 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

HighTower Advisors first reported a position in ACRS in Q2 2016 and has held it in 40 quarters since. The position peaked at $4.29M in Q1 2017. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • HighTower Advisors held 305,836 shares of Aclaris Therapeutics worth $1.15M as of Q1 2026.
  • HighTower Advisors sold 112 Aclaris Therapeutics shares in Q1 2026, an estimated $378.
  • Aclaris Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2091 holding.
  • HighTower Advisors first reported a position in Aclaris Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • HighTower Advisors's Aclaris Therapeutics position peaked at $4.29M in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.